Navigation Links
Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

SAN DIEGO, Nov. 27, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the 25th Annual Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for Tuesday, December 3rd  at 11:00 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which the Company is evaluating in the Light Study, a cardiovascular outcomes trial being conducted under a Special Protocol Assessment (SPA) with the FDA. Based on successful results of the Light Study, the Company plans to resubmit the Contrave NDA to the FDA with potential approval by June 2014.The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Announces Successful Interim Analysis of Contrave Light Study
2. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
5. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
6. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
7. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
8. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
9. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
10. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
11. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 21, 2014  Particle Sciences, ... devices, has developed and manufactured a new innovative ... the Research and Development arm of Exeltis Pharmaceuticals.  ... of Project Management at Particle Sciences, "This vaginal ... utilizing our material sciences and modeling expertise.  We ...
(Date:11/22/2014)... Nov. 21, 2014 Many power shifts ... growing influence of patients in the biopharmaceutical market ... Now, more than ever, understanding how to effectively ... products is essential. According to ... benchmarked companies spent about two-thirds of their patient-focused ...
(Date:11/21/2014)... Nov. 21, 2014  The University of Maryland,s A. ... ceremonial groundbreaking of the new A. James Clark Hall ... building will cultivate transformative new engineering and biomedical technologies ... place at 10:00 a.m. on November 21 at the ... Parking Lot, adjacent to the Jeong H. Kim Engineering ...
Breaking Medicine Technology:Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4
... Study evaluates the efficacy of new device for detecting polyps ... ... Fla., Oct. 7 At the American College of,Gastroenterology Annual ... MD presented results from a,multi-institutional clinical study that evaluated the ...
... by ... with Celiac Disease, Additional Data Indicates Potential in Treating Inflammatory ... Corporation,presented results from two clinical studies this week at the ... CLIN 1001-004, the first Phase IIa trial conducted in celiac ...
Cached Medicine Technology:National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6
(Date:11/22/2014)... 23, 2014 Cancer researchers in New ... between intercellular communication tunnels and the growth and spread ... story on the Surviving Mesothelioma website. , ... University of Minnesota have just released their study on ... materials between cells. They found that mesothelioma cells ...
(Date:11/22/2014)... A classic black prom dress will never go ... suppliers, has unveiled its new items of black prom ... at a big discount, up to 70% off. People throughout ... new black prom dresses, made with the best materials, can ... of all customers, the company provides these beautiful outfits in ...
(Date:11/22/2014)... Today, Dylan Queen, a renowned brand in wedding dresses, ... business offers a wide range of special occasion dresses, ... them to create multiple looks easily. , According to ... of chic wedding dresses has been prepared for many ... rates now. Dylan Queen can always create what ladies ...
(Date:11/22/2014)... November 22, 2014 Discount-Dress.com is ... of the firm is to increase the company’s online market ... a new selection of bridesmaid dresses and announced a bridesmaid ... is valid until Dec. 30, 2014. All the dresses from ... inexpensive. , In fact, Discount-Dress.com is very good at ...
(Date:11/22/2014)... "My friend went in for a mammogram ... said an inventor from Cambria Heights, N.Y. "To add ... second time because the first results were inaccurate. Her ... patent-pending MAMO EASY to offer a more comfortable way ... patient from the pain normally involved with this procedure. ...
Breaking Medicine News(10 mins):Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:New Black Prom Dresses from BellasDress.com 2Health News:Dylan Queen Introduces Its New Wedding Dresses 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2
... ST. LOUIS, May 12 Allied Healthcare Products, Inc. (Nasdaq: ... the third quarter ending March 31, 2009, declined from about ... period, to a loss of about $450,000, or a negative ... the third quarter declined about 11 percent, or $1.5 million, ...
... May 12 With today,s release of the ... showing that the nation,s two largest programs are ... urged politicians to work together on reforms of ... Reform efforts will need to recognize the underlying ...
... to Depletion According to Latest Projections WASHINGTON , ... trustees, reports issued earlier today highlight the imperative to ... and Medicare, according to the American Academy of ... programs has deteriorated further during the past year and ...
... (NYSE: BMR ) today announced it has commenced ... pursuant to an effective shelf registration statement filed with the ... net proceeds of the offering to repay a portion of ... credit and for other general corporate and working capital purposes. ...
... people have the same genetic disease, why would one person ... or not at all? For a group of genetic diseases ... and Joubert syndrome the answer lies in one gene ... also seems to increase the risk of progressive blindness in ...
... suggests , , TUESDAY, May 12 (HealthDay News) -- Children,s ... cardiac death (DCD), according to researchers, who asked 124 ... about their policies in 2007 and 2008. , The ... that 72 percent of them had DCD policies, while ...
Cached Medicine News:Health News:Allied Healthcare Posts Third Quarter Loss 2Health News:Allied Healthcare Posts Third Quarter Loss 3Health News:Allied Healthcare Posts Third Quarter Loss 4Health News:Allied Healthcare Posts Third Quarter Loss 5Health News:Concord Coalition Says New Trustees' Report Demonstrates the Importance of Health Care Cost Control 2Health News:Actuaries: Trustees' Reports Warn of Looming Financial Challenges Facing Retirement Programs 2Health News:Actuaries: Trustees' Reports Warn of Looming Financial Challenges Facing Retirement Programs 3Health News:BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock 2Health News:BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock 3Health News:In retinal disease, sight may depend on second sites 2Health News:In retinal disease, sight may depend on second sites 3Health News:Organ Donation Policies Vary Among Children's Hospitals 2
Stainless steel construction to withstand sterilization modalities (EtO, Steris®, and Sterrad®) Wide angle of view...
Stainless steel construction to withstand sterilization modalities (autoclave, EtO, Steris®, and Sterrad®) Fully autoclavable, with both distal and proximal ends uniquely soldered for longe...
ENDOlap™ laparoscopes provide excellent image linearity and flatness of field....
Inquire...
Medicine Products: